Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study

DOI: 10.1111/j.1440-1843.2007.01176.x
Respirology, 2008, 13, 916-8.

#	Paper	IF	Citations
32	3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension. *Journal of Pharmacy and Pharmaceutical Sciences*, **2009**, 11, 118s-130s	3.4	13
31	Advances in therapies for pediatric pulmonary arterial hypertension. *Expert Review of Respiratory Medicine*, **2009**, 3, 265-82	3.8	4
30	PDE5 inhibitors in non-urological conditions. *Current Pharmaceutical Design*, **2009**, 15, 3521-39	3.3	24
29	Recent Advances in the Management of Pulmonary Arterial Hypertension. *Current Respiratory Medicine Reviews*, **2009**, 5, 41-48	0.3	
28	Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. *Pharmacology & Therapeutics*, **2009**, 122, 216-38	13.9	273
27	Non-congenital heart disease associated pediatric pulmonary arterial hypertension. *Progress in Pediatric Cardiology*, **2009**, 27, 13-23	0.4	18
26	Current Opinion in Cardiology. Current world literature. *Current Opinion in Cardiology*, **2009**, 24, 380-93	2.1	
25	Current world literature. *Current Opinion in Rheumatology*, **2009**, 21, 656-65	5.3	
24	Pharmacotherapeutic management of pulmonary arterial hypertension. *Cardiology in Review*, **2010**, 18, 148-62	3.2	47
23	Pharmacologic and pharmacokinetic rationale for combination therapy in pulmonary arterial hypertension. *Journal of Cardiovascular Pharmacology*, **2010**, 56, 686-95	3.1	3
22	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. *Vascular Health and Risk Management*, **2010**, 6, 273-80	4.4	21
21	Tadalafil for the treatment of pulmonary arterial hypertension. *Expert Opinion on Pharmacotherapy*, **2010**, 11, 127-32	4	27
20	[Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension]. *Archivos De Bronconeumologia*, **2011**, 47 Suppl 7, 26-31	0.7	
19	Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. *Clinical Therapeutics*, **2011**, 33, 993-1004	3.5	27
18	The management of Eisenmenger syndrome in the modern treatment era: a case report. *European Respiratory Review*, **2011**, 20, 293-6	9.8	7
17	Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. *Respiratory Medicine*, **2012**, 106, 730-9	4.6	20
16	Tadalafil for the treatment of pulmonary arterial hypertension. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 747-55	4	13

15	Pediatric Pulmonary Hypertension. **2012**, 730-752		
14	Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. *Therapeutic Advances in Respiratory Disease*, **2013**, 7, 39-49	4.9	13
13	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. *Global Cardiology Science & Practice*, **2014**, 2014, 257-90	0.7	10
12	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. *Core Evidence*, **2015**, 10, 99-109	4.9	19
11	Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. *Circulation*, **2015**, 132, 2037-99	16.7	624
10	Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2015**, 20, 395-400	2.6	2
9	Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension. *Experimental Biology and Medicine*, **2015**, 240, 121-7	3.7	8
8	Advanced Therapy in Eisenmenger Syndrome: A Systematic Review. *Cardiology in Review*, **2017**, 25, 126-132	3.2	6
7	Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. *European Respiratory Review*, **2017**, 26,	9.8	40
6	A review of therapeutic agents for the management of pulmonary arterial hypertension. *Therapeutic Advances in Respiratory Disease*, **2017**, 11, 46-63	4.9	8
5	Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management. *Heart Failure Reviews*, **2020**, 25, 773-794	5	2
4	Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2021**, 26, 453-462	2.6	4
3	Selective Pulmonary Vasodilators. **2015**, 809-836		
2	A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension. *Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery*, **2010**, 26, 206-218	0	1
1	Abordagens Terapêuticas na Síndrome de Eisenmenger: Uma Revisão Sistemática / Therapeutic Approaches in Eisenmenger Syndrome: A Systematic Review. **2022**, 16, 439-457		0